AGXB01

AGXB01 is a murine surrogate of AGX101, a novel antibody-drug conjugate (ADC) developed by Angiex. It targets Transmembrane-4 L-Six-Family-Member-1 (TM4SF1), an endothelial marker and tumor cell antigen that is significantly upregulated in angiogenic tumor vascular endothelium and various cancers, including lung, kidney, ovarian, gastrointestinal, and breast cancers. AGXB01 consists of a TM4SF1-directed antibody conjugated to a potent maytansinoid tubulin inhibitor payload. The drug operates through three distinct mechanisms of action: direct tumor cell killing, deprivation of tumor blood supply by targeting the tumor microenvironment vasculature, and activation of tumor immune surveillance. Preclinical studies in syngeneic mouse models, such as CT26 colon carcinoma and Renca renal cancer, have demonstrated that AGXB01 can potentiate the effects of immune checkpoint inhibitors (ICIs) like anti-PD-1 and anti-CTLA-4 antibodies, leading to high response rates and durable immune memory.

Other names

AGX101 murine surrogateAGX-101 murine surrogateAGX 101 murine surrogate